First Round of Abstract Submission Ends: Dec 30, 2026
Extended Early Bird Ends: Dec 28, 2026
Keynote Speakers
Prof. Avraham A. Levy
Weizmann Institute of Science, Israel
Title: To be confirmed.
Prof. Avraham Levy received a Ph.D. in plant genetics from the Weizmann Institute of Science, Israel, in 1987. He conducted postdoctoral research at Stanford University, USA, and INRA, France. In 1992, he joined the Weizmann Institute, where he served as Department head and Dean. His research addresses the mechanisms underlying the plasticity and biodiversity of plant genomes, including DNA recombination and repair, and polyploidization. He is using these mechanisms to develop precise genome-engineering methods for sustainable food production systems. He is a recipient of the Landau Prize in Plant Sciences (2016), an Advanced ERC grant, the Enid MacRobbie Corresponding Membership Award for 2023 from the American Society of Plant Biology, and an Associate member of the French Academy of Agriculture, and serves as a Reviewing editor for The Plant Cell.
Prof. Thierry Voet
Belgium
Title: Single-Cell and Spatial Multi-Omics to study Human Development, Ageing and Diseases
Thierry Voet graduated with a Master in Bioscience Engineering: Cell and Gene Biotechnology from the University of Leuven (KU Leuven, Belgium), and holds an inter-university post-graduate in Human Genetics. Following his PhD in the Human Genome Laboratory at KU Leuven, he pioneered single-cell microarray analyses, and in 2010, he joined in the Cancer Genome Project at the Wellcome Sanger Institute (Cambridge, UK) to explore next-generation sequencing technologies for single-cell genomics, which led to an Associate Faculty membership. In 2014, he became Associate Professor at KU Leuven following a tenure track, and was appointed Professor in 2017 and Full Professor in 2022. He is lead-founder and Director of the KU Leuven Institute for Single Cell Omics (LISCO). His research focuses on (1) the development of methods for single-cell and spatial multi-omics, and (2) their application to study the biology of cellular heterogeneity in human development, aging and disease.
Dr. PRIOLEAU Marie-Noelle
France
Title: Genome-wide mapping of common fragile sites in neural precursor cells highlights genes in neuropathologies and brain tumorigenesis
M-N Prioleau, director of research at Inserm, leads a team at the Jacques Monod Institute (IJM, Paris, France). She obtained her PhD in Molecular biology in 1994, working with Dr. M. Méchali. Then, M-N Prioleau stayed for three years in the laboratory of Dr. G. Felsenfeld at the NIH (Bethesda, USA). In 1998, she joined the team of O. Hyrien at the ENS in Paris where she started to work on mechanisms involved in origin selection. In 2005, she joined the IJM to establish her laboratory. Her group was the first to map replication origins at a large scale in human cells, to explore the link between replication origins and epigenetic marks, to demonstrate the role of G-quadruplex (pG4) in the activity of model origins and finally to identify dimeric pG4s as key organizers of replication origins in vertebrates. More recently, the team has focused on identifying chromosomal fragile regions during human brain development using brain organoids as a model system.
Prof. Alexandre Reymond
University of Lausanne, Switzerland
Title: To be confirmed
Alexandre Reymond carried out his thesis in the laboratory of Dr. Viesturs Simanis at the Swiss Institute for Experimental Cancer Research (ISREC) and received his Ph.D. from the University of Lausanne in 1993. After completion of his postdoctoral training with Dr Roger Brent in the Department of Molecular Biology, Massachusetts General Hospital and in the Department of Genetics, Harvard Medical School in Boston, he moved to the Telethon Institute of Genetics and Medicine (TIGEM) in Milan in 1998 to lead a research group. He joined in 2000 the Department of Genetic Medicine and Development, University of Geneva Medical School. He moved to the Center for Integrative Genomics in October 2004 and was its Director from 2015 to 2022. He is a past President of the European Society of Human Genetics (2019-2021) and was the Chair of its Scientific Program Committee from 2020 to 2026.
Dr. Valérie Pezo
Genoscope, Institut François Jacob, France
Title: From Xeno-Nucleic Acids to Bacteriophage Genomes with modified DNA
Will update soon
Prof. Alain R. Thierry
Université de Montpellier, France
Title: Circulating DNA: Opening a New Dimension in Genomics
Following pioneering works on gene therapy solutions for cancer and HIV and on DNA auto-organization complex formation in the US (Georgetown Lombardi Cancer Center, Washington DC; and NCI, Bethesda, Prof RC Gallo, chief), A.R. Thierry's contributed to circulating DNA (cirDNA) implementation in clinic and basic research, especially in oncology. In particular, his work at the IRCM-INSERM (Montpellier, France) where he leads the "Biomarkers for Precision Oncology" team, focused on the structure, origins and function of cirDNA. He also coordinated studies on the clinical validation and the clinical utility in using cirDNA analysis. He now conducts research on the impact of neutrophil extracellular traps (NETs) on cirDNA biology and inflammatory diseases. He has pioneering works on cirDNA fragmentation, and proposes potential solutions towards cancer screening with using fragmentomics expanding the boundaries of genomics.
Prof. Davor Lessel
University Regensburg, Germany
Title: From Ultra-Rare Patients to Fundamental Principles of Human Biology
Prof. Davor Lessel is Professor and Chair of Human Genetics at the University of Regensburg and Head of the Institute of Human Genetics and the Institute of Clinical Human Genetics at University Hospital Regensburg, Germany. Before moving to Regensburg, he served as Professor and Head of the Institute of Human Genetics at University Hospital Salzburg, Austria. He is a physician-scientist whose research extends beyond classical human genetics into functional genomics, RNA biology, molecular biophysics, and translational medicine. His work seeks not only to identify disease-causing genes, but to understand in quantitative molecular detail how genetic variation perturbs cellular systems and gives rise to human disease. His research spans the human life course, from genetic mechanisms contributing to embryonic and fetal lethality, through neurodevelopmental disorders, to premature ageing and cancer-related mechanisms. His group combines genomic discovery with functional studies, CRISPR/Cas genome engineering, patient-derived iPSC models, and quantitative molecular analyses to connect genetic variation with disease mechanisms. In parallel, his laboratory explores how these mechanistic insights can be translated into new therapeutic concepts, including the development and characterization of small molecules targeting fundamental cellular pathways.
Dr. Yiwen Chen
University of Texas MD Anderson Cancer Center, USA
Title: Large-scale approaches for decoding the "dark" proteome in human cancer
Dr. Yiwen Chen is an Associate Professor in the Department of Bioinformatics and Computational Biology at The University of Texas MD Anderson Cancer Center. He received his Ph.D. in Physics/Biophysics from the University of North Carolina at Chapel Hill and completed postdoctoral research training at Harvard Medical School and the Dana-Farber Cancer Institute.
Dr. Chen’s laboratory focuses on developing and applying cutting-edge computational, AI-powered, and multi-omic integrative frameworks to decode complex biological systems. His research integrates bulk and single-cell/spatial translatomics (Ribo-seq), proteogenomics, and multi-omics data to uncover novel translation events, particularly the identification, characterization, and functional impact of cryptic non-canonical open reading frames (ORFs), and their roles in tumor progression and cancer immunology. On the translational side, his group leverages these functional non-canonical translation products and RNA-mediated regulatory networks to identify novel therapeutic targets and predictive multi-omic biomarkers for targeted therapy and immunotherapy.
Prof. Etienne Bucher
Agroscope, Switzerland
Title: Crop genome dynamics in the context of climate change
Etienne Bucher studied plant virology at Wageningen University and then researched epigenetic mechanisms at the Gregor Mendel Institute in Vienna and at the University of Geneva. He was leading research groups at the University of Basel, at INRAe in France and finally at Agroscope in Switzerland. At Agroscope his research group develops novel breeding approaches to adapt crops to climate change. He has led an ERC Consolidator project on epigenetics, transposable elements and crop breeding.
Prof. Arnold Munnich
Necker Enfants Malades Hospital, France
Title: What can we learn from Mendelian forms of autism spectrum disorders?
Arnold Munnich is a medical doctor since 1979, he received a PhD in sciences in 1988 under the direction of Axel Kahn.
In 1989, he was appointed professor of genetics at the University of Paris V (René Descartes). At Necker Enfants Malades Hospital, he directed the INSERM unit of « Children genetic handicaps » until 2014.
He is one of the Founders of the Institute IMAGINE (Institut des Maladies Génétiques de l’Enfant) within the Necker Enfants Malades Hospital.
His fields are medicine, pediatrics, genetics and molecular biology. He is known worldwide for the diagnosis of children’s metabolic illnesses.
Scientific Work:
Arnold Munnich has dedicated his research to the identification of the genes responsible of neurological, metabolic, malformed, and sensorial handicaps of children.
At the Necker Enfants Malades Hospital, he has created the department of Genetics, bringing together all the skills necessary to the transfer from research in genetics to practical applications for sick persons and their family.
He has succeeded to put together:
• A unit of research for identification of the genes responsible of handicaps,
• A unit of clinical genetics, and
• A unit of pre and postnatal clinical molecular genetics.
This multi skill group has succeeded to localize more than fifty genes responsible of illnesses:
Among these illnesses, one can quote: the Achodronplasie, the Hirschsprung illness, the Spinal amyotropy, the Holt–Oram syndrome, the Stargardt macular dystrophia, the Leber Amaurose, The Pearson syndrome, the Saethre-Cotzen craniostenose…
Bibliography:
Author or Co-author of more than 1000 scientific papers
Books :
• La Rage d’espérer. La génétique au quotidien (1999) (The mania of hope. The daily genetic).
• Programmé mais libre (2016) (Coded but free)
Honours:
• Member of the French Academy of Sciences since November2004.
• Advisor to the President of France for biomedical and health research (2008-2012)
• Officer of the Legion of d’Honneur (2014)
Scientific Recognitions:
• Jean-Hamburger Prize of the city of Paris (1994).
• Jean –Pierre Lecocq Prize of the French Academy of sciences (1999).
• Eloi Collery Prize of the French Academy of medicine (1999).
• Grand Prize of INSERM (Institut National de la Santé et de la Recherche Médicale (2000).
• Jean Bernard Prize of the Foundation for medical research. (2001).
• Prize of the European Society of Human Genetics (2007).
Prof. Rivka Dikstein
Weizmann Institute of Science, Israel
Title: Translational Regulation and Cross-UTR Interactions through Precise mRNA-End Mapping and Machine Learning
Prof. Rivka Dikstein earned her PhD from the Weizmann Institute of Science and conducted postdoctoral research at the University of California, Berkeley. In 1997, she joined the faculty of Biochemistry at the Weizmann Institute of Science. From 2019 to 2022, she served as Head of the Department of Biomolecular Sciences. In 2022, she was appointed Dean of the Faculty of Biochemistry. Prof. Dikstein is the incumbent of the Ruth and Leonard Simon Professorial Chair of Cancer Research.
Prof. Dikstein investigates one of the most fundamental questions in biology: how the regulatory information encoded in our genes is decoded to produce proteins. Her research aims to achieve a deep mechanistic understanding of the various stages of gene expression, particularly transcription and mRNA translation, the interconnections between these stages, and their roles in disease. Her studies have led to seminal discoveries that have advanced our understanding of the transcriptional control of inflammation and neurodegenerative disease, the coordination between transcription and mRNA translation, and novel mechanisms of translational regulation. Her work has also led to the identification of drugs with potential therapeutic effects against inherited neurodegenerative diseases, cancer, and viral infections.
Dr. Isabelle PERRAULT
Paris, France
Title: From Retinal-Specific Genes to Fundamental Cell Biology: The Expanding Landscape of Retinal Dystrophies and Agnostic Therapies
For more than 30 years, I have investigated the molecular and cellular mechanisms underlying severe and early-onset retinal dystrophies (EOSRD), combining expertise in genetics, molecular biology, and cell biology.
In 2014, I developed a high-throughput sequencing panel for the identification of disease-causing variants in EOSRD. This approach enabled us to establish the genetic diagnosis in 87% of patients from a cohort recruited through the Ophthalmic Genetics Department. For the remaining 13%, I continue to investigate the underlying genetic causes using whole-exome and whole-genome sequencing, including both short- and long-read technologies, combined with transcriptomic and/or proteomic approaches.
These complementary strategies have led to the identification of novel disease genes and have revealed the involvement of TUBB4B (Luscan et al., 2017; Dodd et al., 2024), RIMS2 (Méchaussier et al., 2020), and GPATCH11 (Zanetti et al., 2024) in syndromic forms of retinal dystrophy. More recently, germline variants in DDX41, inherited in a recessive manner, were identified as a cause of SERDs (Mars et al., 2026).
The cellular and animal models developed in my laboratory provide valuable tools for investigating the pathophysiological mechanisms underlying retinal degeneration and for understanding how genetic defects ultimately lead to retinal dysfunction and disease.
Prof. Jean-François Deleuze
Université Paris-Saclay, France
Title: To be confirmed.
Will update soon.
Prof. Florent Hubé
CNRS, France
Title: snoRA40 and snoRA70 restore a pseudo-normal phenotype of cells from patients with Myotonic Dystrophy type 1 (DM1)
Florent Hubé, Ph.D., is a senior researcher at the National Center for Scientific Research (CNRS) within the Development, Adaptation, and Aging (Dev2A) laboratory at Sorbonne University in Paris, France. After completing his Ph.D. in Molecular and Cellular Biology in 2003, he conducted postdoctoral research in Canada and France before joining the CNRS in 2013. His research focuses on the role of non-coding RNAs in gene expression, epigenomic regulation, and cell differentiation. His recent work focuses on the diversity, biogenesis, and functions of small non-coding RNAs, particularly small nucleolar RNAs (snoRNAs), in skeletal muscle differentiation and human diseases. One of the main focuses of his research is to understand how the dysregulation of snoRNAs contributes to the pathophysiology of myotonic dystrophy type 1 (MD1), with the broader goal of uncovering new RNA-mediated mechanisms of gene regulation
Prof. Geneviève Almouzni
CNRS / Institut Curie, France
Title: Histone variants and their chaperones, a choreography linked to cell fate and disease
Dr. Geneviève ALMOUZNI is a CNRS Research Director in France. She joined Institut Curie in 1994 to lead a research team on chromatin dynamics and served as Unit Director from 1999 to 2015. From 2013 to 2018, she headed the Institut Curie Research Center (Honorary Director since then). She also oversaw Advanced Education Programs at the Institute.
She is a world leader in understanding genome organization and function during development and disease, particularly cancer. Combining biochemistry, cell biology, physical approaches with advanced imaging, her work has uncovered key molecular mechanisms involved in chromatin assembly and genome regulation.
Author of more than 260 publications, she filed five patents, and received prestigious grants, including ERC Advanced Grants and a Proof of Concept. She coordinated the European EpiGeneSys Network of Excellence, co-chaired the European LifeTime initiative, led the French LabEx DEEP program, and since 2024 has served as scientific coordinator of the PEPR Cell-ID program on "cellular identities and destinies".
She has received numerous distinctions, including Officer of the Order of Merit (2017), Knight of the Order of Academic Palms (2021), and Officer of the Legion of Honor (2024). International awards include the FEBS/EMBO Women in Science Award (2013), the FRM Grand Prize (2014), and the L'Oréal-UNESCO International Award for Women in Science (2024).
She served on the EMBO Council and the ERC Scientific Council (2019–2025), chaired the ERC Gender and Diversity Working Group and the EU-LIFE alliance, and serves on the Human Cell Atlas coordination board. She is a member of the French Academy of Sciences, EMBO, and AAAS. Throughout her career, she has actively promoted science, diversity, and careers of young people and women.
Dr. Marie-Claude Potier
CNRS, Paris Brain Institute, France
Title: Living with an extra chromosome 21: from mechanisms to therapies
My early work during my PhD in Neuropharmacology demonstrated that in vivo, benzodiazepine receptor occupancy predicts pharmacological effects (Potier et al. Mol. Pharmacol 1988), before I moved into molecular biology at the Laboratory of Molecular Biology, MRC, Cambridge, UK, and contributed to the identification of tau splicing variants involved in neurofibrillary tangles in Alzheimer’s disease (Goedert et al. EMBO J. 1989). After joining CNRS, I focused on human chromosome 21 where the APP gene involved in Alzheimer’s disease pathology maps, identifying its first large segmental duplication and contributing to the map used for sequencing (Potier et al., Dutriaux et al. Genomics 1993, 1994 & 1998). I then shifted to gene expression in Down syndrome (trisomy 21), developing microarray tools and showing that only a subset of triplicated genes is overexpressed (Dauphinot et al. Hum. Mol. Genet. 2005; Ait Yahya-Graison et al. Am. J. Hum. Genet. 2007; Golfier et al. Bioinformatics 2009), while also pioneering single-cell gene expression approaches (Bontoux et al. Lab Chip 2008). At ICM, I established a therapeutic program demonstrating that a single dose of a selective GABAα5 inverse agonist can rescue cognitive deficits in a Down syndrome mouse model (Braudeau et al. J. Psychopharmacol. 2011; Duchon et al. Br. J.Pharmacol 2020; Zorilla de San Martin et al. Elife 2020). In Alzheimer’s disease and Down syndrome, my group showed that membrane cholesterol profoundly alters APP trafficking, Aβ production, and endosomal morphology, findings we also observed in patient cells and linked to synaptojanin-1 (Marquer et al. FASEB J. 2011; Cossec et al. Hum. Mol. Genet. 2012; Marquer et al. Mol. Neurodegener. 2014; Corlier et al. Transl Psychiatry. 2015; Xicota et al. Transl Psychiatry. 2023). We are now investigating APP’s cholesterol-binding site using iPSC-derived neurons and new mouse models and have expanded our work to the locus coeruleus, amyloid pathology in DS and APP-duplication cases, and blood–brain barrier models (Hanbouch et al. Mol. Neurobiol. 2022; Kasri et al. Acta Neuropathol 2024; Fructuoso et al. & Valay & Potier Alzheimers Dement. 2025). Clinically, we identified medium-chain fatty acids predicting brain amyloid in at-risk individuals and we developed refined polygenic risk scores, while more recently extending these approaches to biomarker discovery in psychiatric disorders (Xicota et al. EBioMedicine 2019; Xicota et al. Neurology 2022; Sires et al. Brain Behav Immun. 2025).
Prof. Rongling Wu
Beijing Institute of Mathematical Sciences and Applications, China
Title: Graph Genomics: An Emerging Topological Framework for Mapping and Engineering Complex Traits
Rongling Wu is a Professor at the Beijing Institute of Mathematical Sciences and Applications and the Zeng Siming Chair Professor at the Yau Mathematical Sciences Center, Tsinghua University. He earned his Ph.D. in Quantitative Genetics from the University of Washington and previously served as a Distinguished Professor and Director of the Center for Statistical Genetics at Pennsylvania State University. His research integrates statistics, mathematics, and biology to elucidate the genetic architecture of complex traits and human diseases, with methodological contributions including functional mapping and idopNetwork. He is a Fellow of the American Statistical Association and the American Association for the Advancement of Science.